Palmitoyl piperidinopiperidine, a novel derivative of 10‑hydroxy‑2‑decenoic acid, as a potent and selective anticancer agent against human colon carcinoma cell lines

Ando,Saeko; Fukamachi,Katsumi; Yoshimoto,Eri; Matsumoto,Harutoshi; Iinuma,Munekazu; Suzui,Masumi

doi:10.3892/ijo.2020.5160

Palmitoyl piperidinopiperidine, a novel derivative of 10‑hydroxy‑2‑decenoic acid, as a potent and selective anticancer agent against human colon carcinoma cell lines

Authors:
- Saeko Ando
- Katsumi Fukamachi
- Eri Yoshimoto
- Harutoshi Matsumoto
- Munekazu Iinuma
- Masumi Suzui
View Affiliations

Affiliations: Department of Neurotoxicology, Graduate School of Medical Sciences and Medical School, Nagoya City University, Nagoya, Aichi 467‑8601, Japan, Laboratory of Pharmacognosy, Gifu Pharmaceutical University, Gifu 501‑1196, Japan
Published online on: December 14, 2020 https://doi.org/10.3892/ijo.2020.5160
Pages: 251-265

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study, to the best of our knowledge, is the first systematic study of the inhibitory effects of palmitoyl piperidinopiperidine (PPI; Japan Patent no. 5597427), on colon carcinogenesis. PPI exhibited marked growth inhibitory activity in several human colon carcinoma cell lines, with IC50 values of approximately 0.5‑2.2 µM. In silico docking analysis indicated that PPI could bind to the SH2 domain of signal transducer and activator of transcription 3 (STAT3). PPI markedly inhibited the transcriptional activity of the SW837 cell line. Flowcytometric analysis demonstrated that PPI induced an increase in the number of cells in the G1 phase of the cell cycle, and induced sub‑G1 fractions of cells at a higher concentration level of PPI. In the HT29 and SW837 cells, western blot analyses exhibited that in whole cell lysates, PPI induced a marked decrease in the expression levels of p‑STAT3, but not in the levels of STAT3 in these cells. PPI also induced a marked decrease in the expression levels of both STAT3 and p‑STAT3 in the chromatin fraction. In addition, PPI affected the protein expression levels of cyclin D1, p53, Bcl‑2, Bcl‑xL and vascular endothelial growth factor (VEGF). In the HT29 cells, PPI induced a marked and dose‑dependent increase in the expression levels of Bax, cleaved caspase‑3, cleaved caspase‑7, cleaved caspase‑8, cleaved caspase‑9 and cleaved poly (ADP‑ribose) polymerase (PARP). In animal model systems, PPI inhibited the growth of implanted carcinoma cells, and also induced a significant decrease in the multiplicity of colonic aberrant crypt foci. In addition, a marked and dose‑dependent inhibition of angiogenesis of the chick chorioallantoic membrane was observed. As regards the possible molecular mechanisms, it is suggested that the inhibition of STAT3 by PPI may affect the function of molecules that are related to apoptosis, angiogenesis and cell cycle progression, eventually contributing to the PPI‑induced growth inhibitory effects.

View Figures

View References

1	Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 3:768–780. 2003. View Article : Google Scholar : PubMed/NCBI
2	Lee KW, Bode AM and Dong Z: Molecular targets of phytochemicals for cancer prevention. Nat Rev Cancer. 11:211–218. 2011. View Article : Google Scholar : PubMed/NCBI
3	Ishihara M, Naoi K, Hashita M, Itoh Y and Suzui M: Growth inhibitory activity of ethanol extracts of Chinese and Brazilian propolis in four human colon carcinoma cell lines. Oncol Rep. 22:349–354. 2009.PubMed/NCBI
4	Morioka T, Suzui M, Nabandith V, Inamine M, Aniya Y, Nakayama T, Ichiba T, Mori H and Yoshimi N: The modifying effect of Peucedanum japonicum, a herb in the Ryukyu Islands, on azoxymethane-induced colon preneoplastic lesions in male F344 rats. Cancer Lett. 205:133–141. 2004. View Article : Google Scholar : PubMed/NCBI
5	Morioka T, Suzui M, Nabandith V, Inamine M, Aniya Y, Nakayama T, Ichiba T and Yoshimi N: Modifying effects of Terminalia catappa on azoxymethane-induced colon carcino-genesis in male F344 rats. Eur J Cancer Prev. 14:101–105. 2005. View Article : Google Scholar : PubMed/NCBI
6	Blum MS, Novak AF and Taber S III: 10-Hydroxy-delta 2-decenoic acid, an antibiotic found in royal jelly. Science. 130:452–453. 1959. View Article : Google Scholar : PubMed/NCBI
7	Lerkcer G, Capella P, Conte LS, Ruini F and Giordani G: Components of royal Jelly: I. Identification of the organic acids. Lipids. 16:912–919. 1981. View Article : Google Scholar
8	Sugiyama T, Takahashi K and Mori H: Royal jelly acid, 10-hydroxy-trans-2-decenoic acid, as a modulator of the innate immune responses. Endocr Metab Immune Disord Drug Targets. 12:368–376. 2012. View Article : Google Scholar : PubMed/NCBI
9	Li X, Huang C and Xue Y: Contribution of lipids in honeybee (Apis mellifera) royal jelly to health. J Med Food. 16:96–102. 2013. View Article : Google Scholar : PubMed/NCBI
10	Chen YF, Wang K, Zhang YZ, Zheng YF and Hu FL: In vitro anti-inflammatory effects of three fatty acids from royal jelly. Mediators Inflamm. 2016:35836842016. View Article : Google Scholar :
11	Yatsunami K and Echigo T: Antibacterial action of Royal jelly. Bull Fac Agr Tamagawa Univ. 25:13–22. 1985.
12	Alreshoodi FM and Sultanbawa Y: Antimicrobial activity of royal jelly. Anti-Infective Agents. 13:50–59. 2015. View Article : Google Scholar
13	Sediva M, Laho M, Kohutova L, Mojzisova A, Majtan J and Klaudiny J: 10-HDA, A major fatty acid of Royal jelly, exhibits pH dependent growth-inhibitory activity against different strains of Paenibacillus larvae. Molecules. 23:32362018. View Article : Google Scholar
14	Townsend GF, Morgan JF, Tolnai S, Hazlett B, Morton HJ and Shuel RW: Studies on the in vitro antitumor activity of fatty acids. I 10-Hydroxy-2-decenoic acid from royal jelly. Cancer Res. 20:503–510. 1960.PubMed/NCBI
15	Yang YC, Chou WM, Widowati DA, Lin IP and Peng CC: 10-hydroxy-2-decenoic acid of royal jelly exhibits bactericide and anti-inflammatory activity in human colon cancer cells. BMC Complement Altern Med. 18:2022018. View Article : Google Scholar : PubMed/NCBI
16	Suzui M: An anticancer agent derived from natural fatty acid. Chemical Industry. 66:22–27. 2015.In Japanese.
17	Suzui M and Iinuma M: Anticancer agent. Japan Patent 5597427. 2014
18	Suzui M, Masuda M, Lim JTE, Albanese C, Pestell RG and Weinstein IB: Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1. Cancer Res. 62:3997–4006. 2002.PubMed/NCBI
19	Suzui M, Inamine M, Kaneshiro T, Morioka T, Yoshimi N, Suzuki R, Kohno H and Tanaka T: Indole-3-carbinol inhibits the growth of human colon carcinoma cells but enhances the tumor multiplicity and volume of azoxymethane-induced rat colon carcinogenesis. Int J Oncol. 27:1391–1399. 2005.PubMed/NCBI
20	Suzui M, Sunagawa N, Chiba I, Moriwaki H and Yoshimi N: Acyclic retinoid, a novel synthetic retinoid, induces growth inhibition, apoptosis, and changes in mRNA expression of cell cycle- and differentiation-related molecules in human colon carcinoma cells. Int J Oncol. 28:1193–1199. 2006.PubMed/NCBI
21	Suzui M, Shimizu M, Masuda M, Lim JTE, Yoshimi N and Weinstein IB: Acyclic retinoid activates retinoic acid receptor beta and induces transcriptional activation of p21(CIP1) in HepG2 human hepatoma cells. Mol Cancer Ther. 3:309–316. 2004.PubMed/NCBI
22	Kawamori T, Rao CV, Seibert K and Reddy BS: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58:409–412. 1998.PubMed/NCBI
23	Futakuchi M, Nitanda T, Ando S, Matsumoto H, Yoshimoto E, Fukamachi K and Suzui M: Therapeutic and preventive effects of osteoclastogenesis inhibitory factor on osteolysis, proliferation of mammary tumor cell and induction of cancer stem cells in the bone microenvironment. Int J Mol Sci. 19:8882018. View Article : Google Scholar :
24	Suzui M, Morioka T and Yoshimi N: Colon preneoplastic lesions in animal models. J Toxicol Pathol. 26:335–341. 2013. View Article : Google Scholar
25	Bird RP: Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett. 37:147–151. 1987. View Article : Google Scholar : PubMed/NCBI
26	Kanda Y: Investigation of the freely available easy-to-use soft-ware 'EZR' for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar
27	Yu H and Jove R: The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004. View Article : Google Scholar : PubMed/NCBI
28	Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K, et al: Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: Inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol. 167:969–980. 2005. View Article : Google Scholar : PubMed/NCBI
29	Shuai K, Horvath CM, Huang LH, Qureshi SA, Cowburn D and Darnell JE Jr: Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell. 76:821–828. 1994. View Article : Google Scholar : PubMed/NCBI
30	Weinstock LT, Rost WJ and Cheng CC: Synthesis of new poly-amine derivatives for cancer chemotherapeutic studies. J Pharm Sci. 70:956–959. 1981. View Article : Google Scholar : PubMed/NCBI
31	Carpenter RL and Lo HW: STAT3 target genes relevant to human cancers. Cancers. 6:897–925. 2014. View Article : Google Scholar : PubMed/NCBI
32	Reich NC and Liu L: Tracking STAT nuclear traffic. Nat Rev Immunol. 6:602–612. 2006. View Article : Google Scholar : PubMed/NCBI
33	Fletcher S, Turkson J and Gunning PT: Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. Chem Med Chem. 3:1159–1168. 2008. View Article : Google Scholar : PubMed/NCBI
34	Pfeffer CM and Singh ATK: Apoptosis: A target for anticancer therapy. Int J Mol Sci. 19:4482018. View Article : Google Scholar :
35	Lin L, Hutzen B, Li PK, Ball S, Zuo M, DeAngelis S, Foust E, Sobo M, Friedman L, Bhasin D, et al: A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia. 12:39–50. 2010. View Article : Google Scholar : PubMed/NCBI
36	Song H, Wang R, Wang S and Lin J: A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA. 102:4700–4705. 2005. View Article : Google Scholar : PubMed/NCBI
37	Baum O, Suter F, Gerber B, Tschanz SA, Buergy R, Blank F, Hlushchuk R and Djonov V: VEGF-A promotes intussusceptive angiogenesis in the developing chicken chorioallantoic membrane. Microcirculation. 17:447–457. 2010.PubMed/NCBI
38	Fenoglio-Preiser CM and Noffsinger A: Aberrant crypt foci: A review. Toxicol Pathol. 27:632–642. 1999. View Article : Google Scholar : PubMed/NCBI
39	Di Gregorio C, Losi L, Fante R, Modica S, Ghidoni M, Pedroni M, Tamassia MG, Gafà L, Ponz de Leon M and Roncucci L: Histology of aberrant crypt foci in the human colon. Histopathology. 30:328–334. 1997. View Article : Google Scholar : PubMed/NCBI
40	Nucci MR, Robinson CR, Longo P, Campbell P and Hamilton SR: Phenotypic and genotypic characteristics of aberrant crypt foci in human colorectal mucosa. Hum Pathol. 28:1396–1407. 1997. View Article : Google Scholar
41	Shpitz B, Bomstein Y, Mekori Y, Cohen R, Kaufman Z, Neufeld D, Galkin M and Bernheim J: Aberrant crypt foci in human colons: Distribution and histomorphologic characteristics. Hum Pathol. 29:469–475. 1998. View Article : Google Scholar : PubMed/NCBI